Publications by authors named "Jason Hindman"

Claim this Profile
B
Brief Report: Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Participants With Preexisting K65R/N in HIV-1 in Phase 2/3/3b Clinical Trials.
Archana V Boopathy, Michelle L D'Antoni, Kristen Andreatta, Silvia Chang, Jason T Hindman

J Acquir Immune Defic Syndr· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Through the Open-Label Extension of the ALLIANCE Study.
Michelle L D'Antoni, Archana V Boopathy, Kristen Andreatta, Silvia Chang, Jason T Hindman

J Acquir Immune Defic Syndr· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of HIV-1 drug resistance in RNA and proviral DNA genotyping is variable both longitudinally and during repeat testing.
Michelle L D'Antoni, Kristen Andreatta, Silvia Chang, Kirsten White, Hui Liu, Jason T Hindman

J Clin Virol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Evaluation of Drug-Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P-gp Pathways.
Priyanka Arora, Hui Liu, John Ling, Jason T Hindman, Dhananjay D Marathe

J Clin Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of antacid and mineral supplements on bictegravir pharmacokinetics: results from a Phase 1, open-label, drug-drug interaction study.
Priyanka Arora, Jason T Hindman, Steve West, John Ling, Ramesh Palaparthy

Antimicrob Agents Chemother· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Population Pharmacokinetic-pharmacodynamic Modeling of HIV Virus-host Infection Dynamics in Patients Undergoing Antiretroviral Monotherapy.
Alberto Vegas Rodriguez, Nieves Velez de Mendizábal, Yanan Zheng, Jason T Hindman, Ramesh Palaparthy

AAPS J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trials.
Cissy M Kityo, Samir K Gupta, Princy N Kumar, Amy R Weinberg, Bhumi Gandhi-Patel, Jason T Hindman

BMC Infect Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV.
Anton Pozniak, Chloe Orkin, Yazdan Yazdanpanah, Axel Baumgarten, Karam Mounzer, Jason T Hindman

Infect Dis Ther· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV.
Eric S Daar, Chloe Orkin, Paul E Sax, Debbie Hagins, Anton Pozniak, Jason T Hindman

AIDS Res Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis.
Joseph J Eron, Moti Ramgopal, Olayemi Osiyemi, Mehri Mckellar, Jihad Slim, Jason T Hindman

HIV Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study.
Indira Brar, Peter J Ruane, Mezgebe Berhe, Cynthia Brinson, Paul Benson, Jason T Hindman

Medicine (Baltimore)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir-based three-drug regimens in people with HIV with varying adherence to antiretroviral therapy.
Kristen Andreatta, Paul E Sax, David Wohl, Michelle L D'Antoni, Hui Liu, Jason T Hindman

J Antimicrob Chemother· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre-existing HIV resistance and suboptimal adherence.
Kristen Andreatta, Michelle L D'Antoni, Silvia Chang, Aiyappa Parvangada, Ross Martin, Jason T Hindman

J Med Virol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two 5-year studies of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: a plain-language summary.
Paul E Sax, Jason T Hindman, Hal Martin, David Wohl

Future Microbiol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data.
Michelle L D'Antoni, Kristen Andreatta, Silvia Chang, Stephanie Cox, Jason T Hindman

J Acquir Immune Defic Syndr· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.
Chloe Orkin, Andrea Antinori, Jürgen K Rockstroh, Santiago Moreno-Guillén, Claudia T Martorell, Jason T Hindman

AIDS· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study.
Carina A Rodriguez, Eva Natukunda, Renate Strehlau, Esme L Venter, Supattra Rungmaitree, Jason T Hindman

Lancet HIV· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of long-acting lenacapavir in participants with hepatic or renal impairment.
Vamshi Jogiraju, Elijah Weber, Jason Hindman, Steve West, John Ling

Antimicrob Agents Chemother· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV.
Haeyoung Zhang, Jason T Hindman, Ludwig Lin, Maggie Davis, Justin Shang

AIDS· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial.
Anchalee Avihingsanon, Hongzhou Lu, Chee Loon Leong, Chien-Ching Hung, Ellen Koenig, Jason T Hindman

Lancet HIV· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials.
Paul E Sax, José R Arribas, Chloe Orkin, Adriano Lazzarin, Anton Pozniak, Jason T Hindman

EClinicalMedicine· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019.
Richard M Burwick, Sigal Yawetz, Kathryn E Stephenson, Ai-Ris Y Collier, Pritha Sen, Jason Hindman

Clin Infect Dis· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
Jonathan Winston, Michel Chonchol, Joel Gallant, Jacques Durr, Robert B Canada, Jason Hindman

HIV Clin Trials· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
Frank J Palella, Martin Fisher, Pablo Tebas, Brian Gazzard, Peter Ruane, Jason Hindman

AIDS· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The frequency of adjusted renal dosing of tenofovir DF and its effects on patient outcomes.
Jacob A Langness, Jason T Hindman, Steven C Johnson, Jennifer J Kiser

J Pharm Pract· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis